Searched for
NATCO PHARMA CASE
Holding stocks is harder than finding them: 10 mid- and small-caps stocks that may be worth holding on toHolding a stock is not an act of blind faith. It is not refusing to change one’s mind. It is not averaging down because the stock has falle...- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Natco Pharma to buy over 35% in South Africa's Adcock IngramNatco Pharma, based in Hyderabad, is set to acquire a 35.75% stake in Adcock Ingram, South Africa's second-largest drugmaker, for ₹2,000 cr...
- Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent disputeThe Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the paten...
- Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patentThe Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing pu...
- Akash Bhansali picks 2 new stocks, reduces holding in 3 othersLeading market expert, Madhusudan Kela, has invested in Natco Pharma and Praxis Home Retail, acquiring a 1% stake in the former and 2.1% in...
- Natco dares Novartis with new heart drugAccording to data from AIOCD PharmaTrac, an agency that closely tracks pharmaceutical sales, Vymada had sales of Rs 68.3 crore for December...
- Natco takes a beating on FDA observation“The company believes there would be no adverse impact to its current or future pipeline products coming from these facilities,” Natco Phar...
- Natco Pharma shares surge over 9 per centThe stock gained sharply by 9.09 per cent to settle at Rs 1,792.05 on the BSE. During the day, it jumped 10.48 per cent to Rs 1,815 -- its ...
- Natco slumps; US court rules for Teva in drug patent caseUS Supreme Court sends patent case back to lower court. Generic launches by Natco and other pharma companies will be delayed, say analysts.
- Natco Pharma cracks 19% as US justices agrees to hear Teva's Copaxone appealThe decision by the Supreme Court comes at a time when Teva is switching its daily version of Copaxone to twice a week version.
- Bayer challenges IPAB’s compulsory licence order to Natco Pharma on cancer drug Nexavar“We introduce the product after years of research and investment, while companies like Natco merely copy and manufacture the product,” said...
- Novartis tanks 7%, hits 52-week low as SC denies cancer drug patentOther pharmaceutical companies like Natco Pharma, Cipla and Ranbaxy surged 2-5% after the SC denied patent for Novartis' cancer drug Glivec.
- Delhi High Court gives Natco Pharma a week to respond to Bristol-Myers Squibb contempt chargesDelhi HC has given Natco Pharma a week's time to respond to the contempt charges slapped by American firm Bristol-Myers Squibb (BMS).
- Natco Pharma begins sales of Bristol Myers' cancer drug DasatinibHyderabad-based generic drugmaker Natco Pharma has started selling copies of global pharma major Bristol Myers Squibb's cancer drug Dasatin...
- Natco loses US patent suit by Israeli pharma major TevaIndia's Natco Pharma has lost a patent infringement suit in the US filed by Israeli pharma major Teva over sale of Copaxone, a drug used to...
- Natco Pharma plunges after NY court verdictShares of Natco Pharma are witnessing selling pressure after a New York court ruled in favour of Teva in a patent case against the company.
- ViiV Healthcare seeks partners for HIV drug in IndiaGlobal drugmaker ViiV Healthcare is evaluating local partnerships to launch its patented HIV medicine maraviroc in India and is open to a d...
- SEBI turns down Natco Pharma's request on ESOPsSEBI has turned down Natco Pharma's request to give cash to employees who are ready to forgo their entitlement of stock options.
Load More
